Technological Advancements have Accelerated the Diagnostic Process and Paved the way for Patients to Achieve Effective Therapies

 

Down's syndrome is a very common chromosomal disorder that affects people from all over the world. In addition, people with Down's syndrome are more likely to develop congenital heart defects, respiratory and hearing issues, Alzheimer's disease, childhood leukemia, and thyroid disorders. Several of these conditions have improved treatment in recent years as a result of technological developments in medicine and research, allowing many people with Down's syndrome to enjoy healthy lives. As a result, people's life expectancy has risen in recent decades, from 25 in 1983 to 60 now.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-down-syndrome-market

Global Down syndrome market is expected to reach USD 3,489.04 million by 2028 from USD 1,224.81 million in 2020 growing with a CAGR of 14.2% in the forecast period of 2021 to 2028. Increasing demand for advanced medical technologies for diagnostic and treatment purposes and the growing incidence rate of acute and chronic diseases are some of the drivers boosting the growth of the market. Rising geriatric population base, increasing awareness about the availability of treatment options in the developing economies and rising personal disposable income are some other important market growth determinants.

Down syndrome market

Rise in the geriatric population base globally is expected to drive the market's growth rate

Geriatric population is the most susceptible to developing chronic diseases and disorders. Therefore, rising geriatric populace all around the world is extremely vulnerable to developing heart diseases, respiratory diseases and other chronic diseases. This in turn will act as an important market growth determinant. Increased expenditure by public and private players on the development of healthcare infrastructure will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced healthcare technologies will yet again widen the scope of growth.  

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2021 to 2028

Base Year

2020

Historic Years

2019 (Customizable to 2013 - 2018)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Disease Type (Trisomy 21, Translocation Down Syndrome, Mosaic Down Syndrome), Treatment (Diagnosis, Therapy), End User (Hospital, Clinics, Homecare Setting, Therapy Centers, Others), Distribution Channel (Direct Tender, Retail Sales, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Natera, Inc. (U.S.), Next Biosciences (South Africa), AtilaBiosystems (U.S.), Myriad Genetics, Inc. (U.S.), PerkinElmer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Demeditec Diagnostics GmbH (Germany), Thermo Fisher Scientific Inc. (U.S.), Abnova Corporation (Taiwan), Novus Biologicals (U.S.), Mayo Clinic Health System (U.S.), Boys Town National Research Hospital (U.S.), Boston Children's Hospital (U.S.), Kid Sense Child Development Corporation Pty Ltd (Australia), Down Syndrome Cork (Ireland), Children's Hospital Colorado (U.S.), ASDclinic.co.uk (U.K.), Abbott (U.S.), Physio.co.uk. (U.K.), Illumina, Inc. (U.S.) among others.             

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The Down syndrome market is categorized into four notable segments which are based on disease type, treatment, end user and distribution channel.

  • On the basis of disease type, the Down syndrome market is segmented into trisomy 21, translocation Down syndrome and mosaic Down syndrome. In 2021, Trisomy 21 segment is expected to dominate the market with 92.59% market share because of increasing prevalence of Down syndrome caused due to presence of three copies of chromosome number 21. Moreover as per the published reports trisomy 21 accounts for 98% of Down syndrome cases.
  • On the basis of treatment, the Down syndrome market is segmented into diagnosis and therapy. In 2021, diagnosis segment is expected to dominate the market with 87.46% market share as pregnant women have been recommended to undergo non- invasive prenatal testing to check the chromosomal aberration that can affect the growth of developing fetus. This chronic villus sampling is also performed for confirmation of better health of developing baby among other types of diagnostic methods.
  • On the basis of end user, the Down syndrome market is segmented into hospital, clinics, homecare setting, therapy centers and others. In 2021, the hospital segment is expected to dominate the market with 57.60% market share because a large number of pregnant women suffering from Down syndrome visits to achieve accurate diagnosis that leads to adoption of appropriate treatment option. Presence of highly skilled professionals at hospitals is driving the market growth. Moreover, hospitals outpatients' clinics have skilled professionals, including audiologists and physiotherapists, who are especially engaged in providing specific treatment for Down syndrome-associated complications.
  • On the basis of distribution channel, the Down syndrome market is segmented into direct tender, retail sales, others. In 2021, direct tender segment is expected to dominate the market with 73.46% market share as the primary source of procurement in hospitals and clinics. With the increasing cost of healthcare, hospitals are focusing on better services for patients. Procurement of products through direct tender is more reliable for healthcare providers as they are bought in under terms of contract for service.

Major Players

Data Bridge Market Research recognizes the following companies as the major Down syndrome market players in advanced wound care market are Natera, Inc. (U.S.), Mayo Clinic Health System (U.S) and Abbott (U.S.).

Down syndrome market

Market Development

  • In October 2019, Abnova Corporation launched a large collection of mutaFISH probe bioreagents used to energize the FISH (fluorescent insitu hybridization) technique. This mutaFISH probes are widely used for detection of urine's free DNA and plasma RNA and DNA, moreover these are also used for detection of chromosomal aberration leads to trisomy including Down syndrome among others.
  • In November 2019, F. Hoffmann-La Roche Ltd received approval for first non-invasive prenatal test by Health Canada. This test is highly adopted for the determination of the probability of trisomy 21 and other common types of aneuploidies.
  • In June 2019, Illumina, Inc. expanded the version of VeriSeq NIPT Solution (a comprehensive automated solution), which is used for screening of broad range of chromosomal and non-chromosomal abnormalities associated with birth defects. This product is widely used for detection of Down syndrome among other trisomies. The product is now available in Israel, Australia and New Zealand.

Regional Analysis

Geographically, the countries covered in the Down syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in proton therapy market during the forecast period 2021 - 2028

North America is dominating the global Down syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. The U.S. is dominating due to the presence of major market players which provide the wide drug portfolio and well-developed healthcare infrastructure in this region. Also, existence of advanced healthcare technologies in this region is another reason for this region's dominance in the global market.   

Asia-Pacific is estimated to be the fastest growing region in proton therapy market the forecast period 2021 - 2028

Asia-Pacific is expected to grow during the forecast period due to the increasing patient population and rapid development of infrastructural facilities in emerging economies in this region. In addition to this, rising private and public expenditure on the development of healthcare industry infrastructure in the developing and backward economies and increasing per-capita income are expected to propel the market's growth rate in this region. Also, the increasing geriatric population base, surging incidence rate of chronic and acute disorders and diseases, and rising medical tourism are important market growth determinants.

COVID-19 Impact Analysis

There were no precise diagnostic tests available to detect COVID-19 in patients during the epidemic's early stages. Initially, alternative diagnostic tests were attempted, but they were ineffective. Because specialized COVID-19 diagnostic tests were unavailable, diagnostic companies saw an opportunity to market their COVID-19 diagnostic kits. COVID-19 diagnostics kits were brought into local and global markets by a number of significant firms as well as several start-ups from various nations. These companies had an advantage over other diagnostics companies by capitalizing on the need for COVID-19 diagnostic tests, which allowed them maintain income during the crisis. However, many countries' supply chains for the raw materials needed to make diagnostic instruments and products for Down syndrome have been affected as a result of the pandemic. Furthermore, diagnostic product market growth is slowing as a result of the epidemic, as producers of these treatments have restricted production. As a result, the Down syndrome market is projected to be significantly impacted.

For more detailed information about the Down syndrome market report, click here – https://www.databridgemarketresearch.com/reports/global-down-syndrome-market